Experience

Regeneron

• United States
• Biotechnology
• 700 & Above Employee

• Clinical Scientist

  • Apr 2018 - Present



Icahn School of Medicine at Mount Sinai

• United States
• Hospitals and Health Care
• 700 & Above Employee

• • Nov 2016 - Mar 2018

  Tisch Cancer Institute

• • Jul 2016 - Oct 2016

• • Jul 2013 - Jun 2016

• • Jan 2013 - Jul 2013

  Research focus: Investigated role of lymphatic vascular niche in breast cancer resistance to chemotherapy.Project leader, trained and supervised personnel such as research associates and graduate students. Independently employed technical skills in cancer cell and molecular biology. Applied managerial skills to design, execute, analyze, and deliver bi-monthly research results.

• • Jan 2010 - Dec 2012

  Research focus: The role of lymphatic endothelium (LECs) in breast cancer metastasis.Effectively employed knowledge from current scientific literature in experimental designs.Communicated research results to Associate Professor through written reports, oral presentations, and publications. Compiled research data to support grant applications.

• • Mar 2008 - Dec 2009

  Studied lymphangiogenesis of dermal lymphatic vessels in the mouse ear and draining cervical lymph nodes upon intradermal AdHGF and AdVEGF-C delivery. Demonstrated synergistic effect of c-MET and VEGFR-3 signaling during lymphangiogenesis in vivo. These findings identified HGF as a novel, potent lymphangiogenesis factor, and also indicated that c-MET might serve as a new target for inhibiting pathological lymphangiogenesis.



Institute of Chemical Technology, Prague, CZ and Mount Sinai School of Medicine, New York

• PhD student in Biochemistry

  • Sep 2002 - Feb 2008

  Established the procedure for the isolation of human primary lymphatic and blood endothelial cells. Through molecular analysis provided the insight into differences between the blood and lymphatic vasculature on the protein and RNA level. By employing a co-culture assay of LECs with human monocyte-dendritic cells (DC), demonstrated the capability of inflamed lymphatic endothelium to modulate DC phenotype and their capacity to stimulate the proliferation of allogeneic T cells upon adhesive interactions in vitro. Challenged the dogma about the lymphatic system as a passive conduit for immune cells and presented the first evidence for direct control of immune response by the lymphatic endothelium by demonstrating the role of ICAM-1 expressed on LECs on maturation status of migrating DCs to lymph nodes in vivo. Show less